La cadena de opciones muestra datos clave de las opciones de acciones de Crescent Capital BDC a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Crescent Capital BDC..

Crescent Capital BDC (NASDAQ:CCAP) Bolsa, Cadena de Opciones

Crescent Capital BDC

Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.

Crescent Capital BDC, Inc. - Common Stock

Crescent Capital BDC Inc

WIIM

American Eagle Outfitters shares are trading lower after the company guided Q1 revenue down ~3% and withdrew FY25 guidance.

Lendway (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDWY#NASDAQ">LDWY</a>) reported quarterly earnings of $0.25 per share. This is a 135.21 percent increase over losses of $(0.71) per share from the same period last year. The company reported $12.44 million in sales this quarter. This is a 54.90 percent increase over sales of $8.03 million the same period last year.

Earnings

News

LDWY

Lendway Q1 EPS $0.25 Up From $(0.71) YoY, Sales $12.44M Up From $8.03M YoY

Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) reported quarterly losses of $(1.39) per share which beat the analyst consensus estimate of $(3.02) by 53.97 percent. This is a 83.07 percent increase over losses of $(8.21) per share from the same period last year. The company reported $1.32 million in sales this quarter. This is a 331.69 percent increase over sales of $305.72 thousand the same period last year.

Earnings Beats

ENSC

Ensysce Biosciences Q1 EPS $(1.39) Beats $(3.02) Estimate, Sales $1.32M Up From $305.72K YoY

Earnings Misses

NUTX

Nutex Health Q1 EPS $2.56 Misses $3.90 Estimate, Sales $211.79M Beat $134.24M Estimate

Marchex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHX#NASDAQ">MCHX</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.02) by 100 percent. This is a 100 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $11.40 million which missed the analyst consensus estimate of $11.92 million by 4.35 percent. This is a 1.48 percent decrease over sales of $11.57 million the same period last year.

MCHX

Marchex Q1 Adj. EPS $(0.04) Misses $(0.02) Estimate, Sales $11.40M Miss $11.92M Estimate

Commodities

Econ #s

Markets

API Weekly Crude Oil Stock 4.287M Barrel Build vs 2.4M Barrel Draw Est.

AEO Inc. Reports Preliminary First Quarter Results
&nbsp;
Preliminary Results Reflect An Inventory Write Down to Better Align with Demand Trends, and Asset Impairment Charges
&nbsp;
Withdrawing Fiscal Year 2025 Guidance
&nbsp;
PITTSBURGH--(BUSINESS WIRE)--American Eagle Outfitters, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) today reported preliminary financial results for the first quarter ended May 3, 2025.
&nbsp;
For the first quarter of 2025, revenue is expected to be approximately $1.1 billion, which represents a decline of roughly 5% compared to the first quarter of last year. Comparable sales are expected to be down approximately 3%, with American Eagle down 2% and Aerie down 4%. Management expects a GAAP operating loss of approximately $85 million and an adjusted operating loss of approximately $68 million for the quarter.
&nbsp;
The adjusted operating loss reflects higher than planned promotional activity in the quarter and an inventory charge of roughly $75 million related to a write-down of spring and summer merchandise. The GAAP operating loss includes an additional asset impairment and restructuring charge of approximately $17 million, primarily related to closing two fulfillment centers as part of its supply chain network optimization project.
&nbsp;
At this time, the company is withdrawing its previously provided fiscal year 2025 guidance due to macro uncertainty and as management reviews forward plans in the context of first quarter results.

Guidance

AEO Reports Preliminary Q1 Results; Sees Q1 Revenue $1.1B Down ~3% YoY; Withdraws FY25 Guidance

Southland Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SLND#AMEX">SLND</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.38) by 78.95 percent. This is a 700 percent decrease over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $239.49 million which beat the analyst consensus estimate of $228.18 million by 4.96 percent. This is a 16.87 percent decrease over sales of $288.10 million the same period last year.

SLND

Southland Holdings Q1 Adj. EPS $(0.08) Beats $(0.38) Estimate, Sales $239.49M Beat $228.18M Estimate

ClearPoint Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPT#NASDAQ">CLPT</a>) affirms FY2025 sales outlook from $36.00 million-$41.00 million to $36.00 million-$41.00 million vs $38.23 million estimate.

CLPT

ClearPoint Neuro Affirms FY2025 Sales Guidance of $36.00M-$41.00M vs $38.23M Est

ClearPoint Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPT#NASDAQ">CLPT</a>) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.16) by 37.5 percent. This is a 37.5 percent decrease over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $8.48 million which beat the analyst consensus estimate of $8.20 million by 3.48 percent. This is a 11.07 percent increase over sales of $7.64 million the same period last year.

ClearPoint Neuro Q1 EPS $(0.22) Misses $(0.16) Estimate, Sales $8.48M Beat $8.20M Estimate

Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) sees Q2 sales of $23.500 million-$26.500 million vs $25.60 million analyst estimate.

SRFM

Surf Air Mobility Sees Q2 Sales $23.500M-$26.500M vs $25.60M Est

Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.20) by 10 percent. This is a 35.29 percent increase over losses of $(0.34) per share from the same period last year.

INTS

Intensity Therapeutics Q1 EPS $(0.22) Misses $(0.20) Estimate

Surf Air Mobility Inc. Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(1.07) by 1.87 percent. This is a 67.56 percent increase over losses of $(3.36) per share from the same period last year. The company reported quarterly sales of $23.51 million which missed the analyst consensus estimate of $23.87 million by 1.52 percent. This is a 23.24 percent decrease over sales of $30.62 million the same period last year.

Surf Air Mobility Inc. Common Stock Q1 EPS $(1.09) Misses $(1.07) Estimate, Sales $23.51M Miss $23.87M Estimate

Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.33) by 54.55 percent. This is a 75.6 percent increase over losses of $(2.09) per share from the same period last year. The company reported quarterly sales of $3.08 million which missed the analyst consensus estimate of $3.32 million by 7.12 percent. This is a 77.52 percent increase over sales of $1.74 million the same period last year.

EVOK

Evoke Pharma Q1 EPS $(0.51) Misses $(0.33) Estimate, Sales $3.08M Miss $3.32M Estimate

Danaos Q1 Adj. EPS $6.04 Misses $6.43 Estimate, Sales $253.30M Beat $242.00M Estimate

Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) reported quarterly losses of $(0.62) per share. This is a 97.67 percent increase over losses of $(26.57) per share from the same period last year. The company reported $858.00 thousand in sales this quarter.

CAMP

Camp4 Therapeutics Q1 EPS $(0.62) Up From $(26.57) YoY, Sales $858.00K

The Plan will terminate on the earlier of the sale of all shares pursuant to the Plan or May 29, 2026.

KVYO

Klaviyo Ceo and Co-Founder Andrew Bialecki To Adopt Pre-Arranged Stock Trading Plan; Bialecki May Sell Up To 8M Shares

Actelis Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.25) by 12 percent. This is a 56 percent increase over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $721.00 thousand which missed the analyst consensus estimate of $1.20 million by 39.92 percent. This is a 0.69 percent decrease over sales of $726.00 thousand the same period last year.

ASNS

Actelis Networks Q1 GAAP EPS $(0.22) Beats $(0.25) Estimate, Sales $721.00K Miss $1.20M Estimate

Intellicheck (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDN#NASDAQ">IDN</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. This is unchanged from the same period last year. The company reported quarterly sales of $4.89 million which beat the analyst consensus estimate of $4.78 million by 2.31 percent. This is a 4.57 percent increase over sales of $4.68 million the same period last year.

Intellicheck Q1 EPS $(0.02) Beats $(0.03) Estimate, Sales $4.89M Beat $4.78M Estimate

Oklo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) reported quarterly losses of $(0.07) per share. This is a 79.41 percent increase over losses of $(0.34) per share from the same period last year.

OKLO

Oklo Q1 EPS $(0.07) Up From $(0.34) YoY

Press Releases

Crescent Capital BDC, Inc. to Host Analyst & Investor Day on June 11, 2024

Crescent Capital BDC, Inc. Schedules Earnings Release and Conference Call to Discuss its Second Quarter Ended June 30, 2024 Financial Results

Crescent Capital BDC, Inc. Reports Second Quarter 2024 Earnings Results; Declares a Third Quarter Base Dividend of $0.42 Per Share, and a Second Quarter Supplemental Dividend of $0.09 Per Share

Crescent Capital BDC, Inc. Schedules Earnings Release and Conference Call to Discuss its Third Quarter Ended September 30, 2024 Financial Results

Crescent Capital BDC, Inc. Reports Third Quarter 2024 Earnings Results; Declares a Fourth Quarter Base Dividend of $0.42 Per Share, and a Third Quarter Supplemental Dividend of $0.07 Per Share

Crescent Capital BDC, Inc. Schedules Earnings Release and Conference Call to Discuss its Fourth Quarter and Fiscal Year Ended December 31, 2024 Financial Results

Crescent Capital BDC, Inc. Reports Fourth Quarter 2024 Earnings Results; Declares a First Quarter Base Dividend of $0.42 Per Share and Series of Special Dividends

Comments

Crescent Capital BDC

Crescent Capital BDC (CCAP) Opciones

Crescent Capital BDC (NASDAQ:CCAP) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL